BT062, an antibody-drug conjugate directed against CD138, shows clinical activity in a phase I study in patients with relapsed or relapsed/refractory multiple myeloma

This article has no abstract
Epistemonikos ID: e23e5120476ac8a74f90bc206e207eadeb5aa81f
First added on: Feb 05, 2025